Global Liver Cancer Diagnostic Market by Screening Type (Laboratory Tests, Imaging, Biopsy, Endoscopy) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast To 2028

Summary of the Report

Global liver cancer diagnostic market was valued at USD 8.25 Billion in 2017. It is expected to grow at an 8.1% healthy CAGR during the forecast period. The market's growth is driven by rising disease incidence and increasing awareness. Adults are most likely to develop hepatocellular carcinoma (HCC). HCC has been linked to several risk factors, including obesity, hepatitis and alcohol-induced liver cirrhosis. There are many screening methods that can prevent it from developing at an early stage, including imaging and lab tests. This helps to increase market growth.

Liver cancer is caused by environmental pollution, excessive alcohol consumption, and smoking. The World Health Organization (WHO) states that alcohol intake is the main cause of 20% to 50% of cases in liver cirrhosis. The WHO estimates that 13% of the world's adult population is obese. This has been a significant increase in obesity since 1980. Non-alcoholic fatty liver disease is more common in obese people. The demand for liver cancer diagnostic services is expected to grow due to the increasing prevalence of hepatitis B/C infections.

The market is also being driven by the increased prevalence of cancer and the adoption of new detection methods. Market growth is also being supported by government initiatives to raise awareness about the disease, and the Affordable Care Act's favorable reimbursement arrangements. It is crucial to determine the stage of cancer before you can choose the right treatment. The available tests are unable to detect the progression of cancer in all cases. Patients are therefore required to undergo confirmatory tests, which can increase the financial burden.

Specific biomarkers and tumor markers provide comparatively better results. This opens up the industry to create tumor-specific biomarkers as well as improved diagnostic procedures for liver cancer. There is a significant need for therapies that provide long-lasting remission and complete cure in the HCC area. This presents an opportunity to create breakthrough treatments and diagnostic procedures.

Screening Type Insights

Screening type segments include imaging, endoscopy and biopsy. Laboratory tests can be used to test blood, urine, or other bodily fluids, in order to detect cancerous cells/tissues. HCC diagnosis laboratory tests include the blood test for Alpha-fetoprotein (AFP), liver function test, and other blood tests to detect tumor markers and clotting factor, immunophenotyping and urinalysis. These tests can detect abnormalities in tissue and cell structure.

To confirm the presence of tumors, imaging tests take pictures of internal organs. Computed Tomography scans, Magnetic Resonance Imaging scans, X-rays, ultrasound and other radiographic tests are available for diagnosing liver cancer. MRI-compatible pacemakers allow for the scanning of pacemakers. Only patients with compatible pacemakers can be eligible for MRI imaging tests to diagnose cancer. The imaging segment will see a significant CAGR (8%) over the forecast period. Other diagnostic tests include biopsy and laparoscopy.

Regional Insights

North America accounted for over 35% of the global market's 2017 market share. With its excellent healthcare coverage, technological advances, and leading position in the global market, the region is expected to continue to hold the top spot for the remainder of the forecast period. The U.S. is the leading market player in North America. The region's high share is due to the large base of targeted population, increased demand for diagnostics, better technology, and rapid adoption of new therapeutics and diagnostic methods.

Asia Pacific is expected the most growth because of the rising incidence of liver cancer in Asia and the growing importance of lowering cancer treatment costs in developing countries like India and China. The demand for diagnostic procedures for liver cancer will rise due to the growing medical tourism industry. The region will also benefit from increased research and development investments as well as favorable government policies that favor healthcare device manufacturers.

Market Share Insights & Key Companies

Globally, the market is extremely competitive. Illumina, Inc., Qiagen, F. Hoffmann-La Roche Ltd., Siemens Healthcare GmbH, and Thermo Fisher Scientific are some of the leading companies in this industry. These companies are focused on expanding their product portfolios and merging and acquiring other companies to retain market share.

Liver Cancer Diagnostics Market Report Scope

The Report Covers Certain Segments

This report forecasts volume and revenue growth at the global, regional and country level. It also provides analysis of industry trends for each sub-segment from 2014-2025. Up Market Research has divided the global liver cancer diagnostic market report by screening type and location.

• Screening Type Outlook Revenue, USD Million, 2014-2025

  • Labor Tests

    • Biomarkers

      • Oncofetal and Glycoprotein Antigens

      • Enzymes and isoenzymes

      • Growth Factors and Receptors

      • Molecular Markers

      • Pathological biomarkers

    • Blood tests

  • Imaging

  • Endoscopy

  • Biopsy

  • Other

• Regional Outlook (Revenue USD Million, 2014-2025)

  • North America

    • The U.S.

    • Canada

  • Europe

    • The U.K.

    • Germany

  • Asia Pacific

    • Japan

    • China

  • Latin America

    • Brazil

    • Mexico

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

These are the most frequently asked questions about this report

b. Market growth is being driven by rising disease incidence, increasing awareness, and increased use of advanced cancer screening tools.

b. Global liver cancer diagnostic market was valued at USD 9.8 Billion in 2019, and is forecast to grow to USD 10.6 Billion by 2020.

b. Global liver cancer diagnostic market will grow at 8.1% compound annual growth rate from 2017 to 2025, reaching USD 15.4 billion in 2025.

b. With a 37.6% share in 2019, laboratory tests dominated the liver-cancer diagnostic market. This is due to rising incidences of liver cancer worldwide. Laboratory tests have a dominant share of the liver cancer diagnostic market at 37.6% in 2019.

b. The market for liver cancer diagnostics is dominated by Illumina, Inc., Qiagen, F. Hoffmann-La Roche Ltd., Siemens Healthcare GmbH, and Thermo Fisher.

Up Market Research published a new report titled “Liver Cancer Diagnostic Market research report which is segmented by Screening Type (Laboratory Tests, Imaging, Biopsy, Endoscopy), By Players/Companies Inc; Qiagen; F Hoffmann-La Roche Ltd; Siemens Healthcare GmbH; and Thermo Fisher Scientific, Illumina”. As per the study the market is expected to grow at a CAGR of XX% in the forecast period.

The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include products, applications, and competitor analysis.

Global Liver Cancer Diagnostic Market Report Segments:

The market is segmented by Screening Type (Laboratory Tests, Imaging, Biopsy, Endoscopy).

Liver Cancer Diagnostic Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report.

Key Benefits for Industry Participants & Stakeholders:

• Industry drivers, restraints, and opportunities covered in the study
• Neutral perspective on the market performance
• Recent industry trends and developments
• Competitive landscape & strategies of key players
• Potential & niche segments and regions exhibiting promising growth covered
• Historical, current, and projected market size, in terms of value
• In-depth analysis of the Liver Cancer Diagnostic Market

Overview of the regional outlook of the Liver Cancer Diagnostic Market:

Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa (MEA). North America region is further bifurcated into countries such as U.S., and Canada. The Europe region is further categorized into U.K., France, Germany, Italy, Spain, Russia, and Rest of Europe. Asia Pacific is further segmented into China, Japan, South Korea, India, Australia, South East Asia, and Rest of Asia Pacific. Latin America region is further segmented into Brazil, Mexico, and Rest of Latin America, and the MEA region is further divided into GCC, Turkey, South Africa, and Rest of MEA.

Highlights of The Liver Cancer Diagnostic Market Report:

1. The market structure and projections for the coming years.
2. Drivers, restraints, opportunities, and current trends of Liver Cancer Diagnostic Market.
3. Historical data and forecast.
4. Estimations for the forecast period 2028.
5. Developments and trends in the market.

                1. Laboratory Tests

                2. Imaging

                3. Biopsy

                4. Endoscopy

7. Market scenario by region, sub-region, and country.
8. Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
9. Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
10. Government Policies, Macro & Micro economic factors are also included in the report.

We have studied the Liver Cancer Diagnostic Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2028.

How you may use our products:

• Correctly Positioning New Products
• Market Entry Strategies
• Business Expansion Strategies
• Consumer Insights
• Understanding Competition Scenario
• Product & Brand Management
• Channel & Customer Management
• Identifying Appropriate Advertising Appeals

Reasons to Purchase the Liver Cancer Diagnostic Market Report:

• The report includes a plethora of information such as market dynamics scenario and opportunities during the forecast period
• Segments and sub-segments include quantitative, qualitative, value (USD Million,) and volume (Units Million) data.
• Regional, sub-regional, and country level data includes the demand and supply forces along with their influence on the market.
• The competitive landscape comprises share of key players, new developments, and strategies in the last three years.
• Comprehensive companies offering products, relevant financial information, recent developments, SWOT analysis, and strategies by these players.